These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 29186393)

  • 1. Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIIA Registry.
    Ruiz Ortiz M; Muñiz J; Raña Míguez P; Roldán I; Marín F; Asunción Esteve-Pastor M; Cequier A; Martínez-Sellés M; Bertomeu V; Anguita M;
    Europace; 2018 Oct; 20(10):1577-1583. PubMed ID: 29186393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Comparison of Inappropriate-Low-Doses Use among 4 Direct Oral Anticoagulants in Patients with Atrial Fibrillation: From the Database of a Single-Center Registry.
    Sato T; Aizawa Y; Fuse K; Fujita S; Ikeda Y; Kitazawa H; Takahashi M; Okabe M
    J Stroke Cerebrovasc Dis; 2018 Nov; 27(11):3280-3288. PubMed ID: 30121155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy.
    Barra ME; Fanikos J; Connors JM; Sylvester KW; Piazza G; Goldhaber SZ
    Am J Med; 2016 Nov; 129(11):1198-1204. PubMed ID: 27341955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration.
    Borne RT; O'Donnell C; Turakhia MP; Varosy PD; Jackevicius CA; Marzec LN; Masoudi FA; Hess PL; Maddox TM; Ho PM
    BMC Cardiovasc Disord; 2017 Sep; 17(1):236. PubMed ID: 28865440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative safety and effectiveness of dabigatran vs. rivaroxaban and apixaban in patients with non-valvular atrial fibrillation: a retrospective study from a large healthcare system.
    Villines TC; Ahmad A; Petrini M; Tang W; Evans A; Rush T; Thompson D; Oh K; Schwartzman E
    Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):80-90. PubMed ID: 30500885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apixaban, Rivaroxaban, and Dabigatran in Patients Undergoing Atrial Fibrillation Ablation.
    Rillig A; Lin T; Plesman J; Heeger CH; Lemes C; Metzner A; Mathew S; Wissner E; Wohlmuth P; Ouyang F; Kuck KH; Tilz RR
    J Cardiovasc Electrophysiol; 2016 Feb; 27(2):147-53. PubMed ID: 26464027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
    Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
    Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants.
    Testa S; Paoletti O; Legnani C; Dellanoce C; Antonucci E; Cosmi B; Pengo V; Poli D; Morandini R; Testa R; Tripodi A; Palareti G
    J Thromb Haemost; 2018 May; 16(5):842-848. PubMed ID: 29532628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inappropriate Dosing of Direct Oral Anticoagulants in Patients with Atrial Fibrillation.
    Sugrue A; Sanborn D; Amin M; Farwati M; Sridhar H; Ahmed A; Mehta R; Siontis KC; Mulpuru SK; Deshmukh AJ; Gersh BJ; Asirvatham SJ; Madhavan M
    Am J Cardiol; 2021 Apr; 144():52-59. PubMed ID: 33385355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.
    Lip GYH; Skjøth F; Nielsen PB; Kjældgaard JN; Larsen TB
    JAMA Cardiol; 2017 Aug; 2(8):872-881. PubMed ID: 28614582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kidney function monitoring and nonvitamin K oral anticoagulant dosage in atrial fibrillation.
    Andreu Cayuelas JM; Caro Martínez C; Flores Blanco PJ; Elvira Ruiz G; Albendin Iglesias H; Cerezo Manchado JJ; Bailen Lorenzo JL; Januzzi JL; García Alberola A; Manzano-Fernández S
    Eur J Clin Invest; 2018 Jun; 48(6):e12907. PubMed ID: 29423910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Thrombocytopenia.
    Janion-Sadowska A; Papuga-Szela E; Łukaszuk R; Chrapek M; Undas A
    J Cardiovasc Pharmacol; 2018 Sep; 72(3):153-160. PubMed ID: 29985282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bleeding Risk of Add-On Anti-Platelet Agents to Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation (From 2216 Patients in the DIRECT Registry).
    Sotomi Y; Hirata A; Amiya R; Kobayashi T; Hirayama A; Sakata Y; Higuchi Y
    Am J Cardiol; 2019 Apr; 123(8):1293-1300. PubMed ID: 30717887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation.
    Hernandez I; Zhang Y; Saba S
    Am J Cardiol; 2017 Nov; 120(10):1813-1819. PubMed ID: 28864318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-life behaviour of direct oral anticoagulants in a Spanish cohort with non-valvular atrial fibrillation: Refase Registry.
    Navarro-Almenzar B; Cerezo-Manchado JJ; Caro-Martinez C; García-Candel F; Flores Blanco PJ; Ruiz GE; Andreu Cayuelas JM; Montoya FA; Cascales A; Lova Navarro A; García Alberola A; Andrés Pascual Figal D; Bailen Lorenzo JL; Manzano-Fernández S
    Curr Med Res Opin; 2019 Dec; 35(12):2035-2041. PubMed ID: 31335222
    [No Abstract]   [Full Text] [Related]  

  • 16. Appropriateness of Dabigatran and Rivaroxaban Prescribing in Qatar: A 5-Year Experience.
    Elewa H; El-Makaty H; Ali Z
    J Cardiovasc Pharmacol Ther; 2018 Mar; 23(2):155-161. PubMed ID: 28978236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.
    Li G; Lip GYH; Holbrook A; Chang Y; Larsen TB; Sun X; Tang J; Mbuagbaw L; Witt DM; Crowther M; Thabane L; Levine MAH
    Eur J Epidemiol; 2019 Feb; 34(2):173-190. PubMed ID: 29948370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Left atrial thrombus and dense spontaneous echocardiographic contrast in patients on continuous direct oral anticoagulant therapy undergoing catheter ablation of atrial fibrillation: Comparison of dabigatran, rivaroxaban, and apixaban.
    Wu M; Gabriels J; Khan M; Shaban N; D'Amato S; Liu CF; Markowitz SM; Ip JE; Thomas G; Singh P; Lerman B; Patel A; Cheung JW
    Heart Rhythm; 2018 Apr; 15(4):496-502. PubMed ID: 29605015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prescribing of Direct Oral Anticoagulants in Atrial Fibrillation Based on Estimation of Renal Function Using Standard and Modified Cockcroft-Gault Equations: A Retrospective Analysis.
    Kucey M; Bolt J; Albers L; Bell A; Iroh N; Toppings J
    Can J Hosp Pharm; 2016; 69(5):409-414. PubMed ID: 27826159
    [No Abstract]   [Full Text] [Related]  

  • 20. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants.
    Halvorsen S; Ghanima W; Fride Tvete I; Hoxmark C; Falck P; Solli O; Jonasson C
    Eur Heart J Cardiovasc Pharmacother; 2017 Jan; 3(1):28-36. PubMed ID: 27680880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.